• 1
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:29812997.
  • 2
    Lindholm LH, Ibsen H, Borch-Johnsen K et al, for the LIFE study group Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002;20:18791886.
  • 3
    Niklason A, Hednet T, Captopril Prevention Project Study Group et al. Development of diabetes is retarded by ACE-inhibition in hypertensive patients — a subanalysis of the Captopril Prevention Project (CAPPP). J Hypertens 2004;22:645652.
  • 4
    Kjeldsen SE, Julius S, VALUE Trial Investigators et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: The VALUE trial. J Hypertens 2006;24:14051412.
  • 5
    Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet 2007;369:201207.
  • 6
    Fukui T, Rahman M, Hayashi K et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: Rationale, design, and methods. Hypertens Res 2003;26:979990.
  • 7
    Ogihara T, Nakao K, Fukui T et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension 2008;51:393398.
  • 8
    Ogihara T, Fujimoto A, Nakao K et al. for the CASE-J trial group ARB candesartan and CCB amlodipine in hypertensive patients: The CASE-J Trial. Expert Rev Cardiovasc Ther 2008;6:11951201.
  • 9
    Messerli FH, Sundgaard-Riise K, Ventura HO et al. Essential hypertension in the elderly: Haemodynamics, intravascular volume, plasma rennin activity, and circulating catecholamine levels. Lancet 1983;2:983986.
  • 10
    Karlsson C, Lindell K, Ottosson M et al. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 1998;83:39253929.